Alzheimer’s disease (AD) is a neurodegenerative condition marked by the accumulation of beta-amyloid (Aβ) plaques and tau neurofibrillary tangles (T), leading to neuronal death and cognitive decline.1,2 These pathological changes often begin decades before the clinical onset of symptoms, underscoring the need for early detection methods to intervene during the preclinical phase of AD.3,4 Early interventions at this stage have the greatest potential to modify disease progression, making the identification of sensitive cognitive markers crucial.5 The gene discussed is MAPT; the disease is Alzheimer disease.